Blood pressure systolic increased adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 19,270 adverse event reports that record the MedDRA preferred term Blood pressure systolic increased. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 891 reports in the 12 months to June 2026 and 1,130 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 662 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 891 (0.1%) record this term. Reports for patients aged 65 to 74 were 21.7% of the reports that record this term and 11.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 133 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Blood pressure systolic increased name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	157
Acetaminophen		136
Aclasta		56
Actemra	Interleukin-6 receptor antagonist	1,429
Adalimumab	Tumor necrosis factor blocker	76
Adempas	Soluble guanylate cyclase stimulator	63
Afinitor	Kinase inhibitor	260
Alendronate sodium	Bisphosphonate	91
Amlodipine	Calcium channel blocker	382
Amlodipine Besilate		74
Amlodipine besylate	Dihydropyridine calcium channel blocker	153
Apremilast	Phosphodiesterase 4 inhibitor	61
Arava	Antirheumatic agent	115
Aspirin	Nonsteroidal anti-inflammatory drug	115
Atenolol	beta-Adrenergic blocker	128
Atorvastatin		153
Atorvastatin calcium	HMG-CoA reductase inhibitor	122
Avastin	Vascular endothelial growth factor inhibitor	61
Azathioprine	Purine antimetabolite	85
Baclofen	gamma-Aminobutyric acid-ergic agonist	94
Benadryl	Histamine-1 receptor antagonist	143
Bevacizumab	Vascular endothelial growth factor inhibitor	77
Bisoprolol	beta-Adrenergic blocker	177
Cabometyx	Kinase inhibitor	137
Celebrex	Nonsteroidal anti-inflammatory drug	182
Certolizumab pegol	Tumor necrosis factor blocker	67
Cimzia	Tumor necrosis factor blocker	117
Ciprofloxacin	Fluoroquinolone antibacterial	101
Clonazepam	Benzodiazepine	189
Codeine		183
Codeine phosphate		69
Cosentyx	Interleukin-17A antagonist	274
Cyclosporine	Calcineurin inhibitor immunosuppressant	122
Cymbalta		137
Desoximetasone	Corticosteroid	77
Diclofenac	Nonsteroidal anti-inflammatory drug	95
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	89
Digoxin	Cardiac glycoside	69
Diltiazem		89
Diovan	Angiotensin 2 receptor blocker	190
Diphenhydramine	Histamine-1 receptor antagonist	79
Diphenhydramine hydrochloride	Histamine-1 receptor antagonist	71
Enbrel	Tumor necrosis factor blocker	179
Enfortumab vedotin		51
Entresto	Angiotensin 2 receptor blocker	218
Erelzi		103
Ergocalciferol	Provitamin D2 compound	81
Etanercept	Tumor necrosis factor blocker	54
Exforge	Angiotensin 2 receptor blocker	59
Folic acid		76
Fosamax	Bisphosphonate	124
Furosemide	Loop diuretic	129
Gabapentin	Anti-epileptic agent	72
Gilenya	Sphingosine 1-phosphate receptor modulator	81
Gliclazide		55
Humira		151
Hydrochlorothiazide	Thiazide diuretic	91
Hydroxychloroquine	Antimalarial	117
Hydroxychloroquine sulfate	Antimalarial	117
Ibuprofen	Nonsteroidal anti-inflammatory drug	131
Imodium	Opioid agonist	52
Indapamide	Thiazide-like diuretic	50
Inflectra	Tumor necrosis factor blocker	865
Infliximab	Tumor necrosis factor blocker	763
Irbesartan	Angiotensin 2 receptor blocker	76
Januvia	Dipeptidyl peptidase 4 inhibitor	63
Leflunomide	Antirheumatic agent	273
Lenvima	Kinase inhibitor	56
Lipitor	HMG-CoA reductase inhibitor	65
Lisinopril	Angiotensin converting enzyme inhibitor	94
Lorazepam	Benzodiazepine	81
Losartan	Angiotensin 2 receptor blocker	58
Lyrica		68
Mepolizumab	Interleukin-5 antagonist	52
Metformin	Biguanide	426
Metformin hydrochloride	Biguanide	175
Methotrexate	Folate analog metabolic inhibitor	862
Methotrexate sodium	Folate analog metabolic inhibitor	146
Methylprednisolone	Corticosteroid	71
Methylprednisolone sodium succinate	Corticosteroid	98
Metoprolol	beta-Adrenergic blocker	198
Metoprolol tartrate	beta-Adrenergic blocker	76
Micardis		89
Montelukast	Leukotriene receptor antagonist	146
Montelukast sodium	Leukotriene receptor antagonist	58
Morphine	Opioid agonist	167
Morphine sulfate	Opioid agonist	144
Motrin	Nonsteroidal anti-inflammatory drug	57
Mycophenolate mofetil	Antimetabolite immunosuppressant	276
Myrbetriq	beta3-Adrenergic agonist	109
Naproxen	Nonsteroidal anti-inflammatory drug	101
Nifedipine	Dihydropyridine calcium channel blocker	56
Northera		98
Norvasc	Calcium channel blocker	52
Octreotide	Somatostatin analog	52
Octreotide acetate	Somatostatin analog	62
Omalizumab	Anti-IgE	694
Omeprazole	Proton pump inhibitor	56
Orencia	Selective T cell costimulation modulator	334
Otezla	Phosphodiesterase 4 inhibitor	112
Palbociclib	Kinase inhibitor	53
Pantoprazole	Proton pump inhibitor	241
Pantoprazole sodium	Proton pump inhibitor	58
Perindopril		73
Perjeta	HER2/neu receptor antagonist	62
Prednisone	Corticosteroid	572
Pregabalin		64
Ramipril	Angiotensin converting enzyme inhibitor	288
Remicade	Tumor necrosis factor blocker	284
Rituxan	CD20-directed cytolytic antibody	561
Rituximab	CD20-directed cytolytic antibody	2,241
Rosuvastatin	HMG-CoA reductase inhibitor	129
Rosuvastatin calcium	HMG-CoA reductase inhibitor	140
Ruxience	CD20-directed cytolytic antibody	131
Sandostatin	Somatostatin analog	1,364
Sandostatin Lar		142
Sandostatin LAR Depot		1,636
Simponi	Tumor necrosis factor blocker	120
Stelara	Interleukin-12 antagonist	105
Sulfamethoxazole		70
Sulfasalazine	Aminosalicylate	177
Tocilizumab	Interleukin-6 receptor antagonist	59
Trastuzumab	HER2/neu receptor antagonist	83
Tylenol	Expectorant	104
Valsartan	Angiotensin 2 receptor blocker	166
Vedolizumab	Integrin receptor antagonist	51
Vioxx		56
Xarelto	Factor Xa inhibitor	56
Xeljanz	Janus kinase inhibitor	111
Xolair	Anti-IgE	974
Zejula	Poly(ADP-Ribose) polymerase inhibitor	62
Zometa		50
Zopiclone		74

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 48 pharmacologic classes with 100 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Blood pressure systolic increased name, in order of name
Class	Reports with this term
Aminosalicylate	191
Angiotensin 2 receptor blocker	1,042
Angiotensin converting enzyme inhibitor	419
Anti-epileptic agent	123
Anti-IgE	1,668
Antimalarial	285
Antimetabolite immunosuppressant	329
Antirheumatic agent	388
Aromatase inhibitor	113
Atypical antipsychotic	191
Benzodiazepine	310
beta-Adrenergic blocker	710
beta3-Adrenergic agonist	109
Biguanide	623
Bisphosphonate	316
Calcineurin inhibitor immunosuppressant	176
Calcium channel blocker	492
CD20-directed cytolytic antibody	2,981
Corticosteroid	1,088
Dihydropyridine calcium channel blocker	211
Expectorant	108
Factor Xa inhibitor	139
Fluoroquinolone antibacterial	175
Folate analog metabolic inhibitor	1,014
HER2/neu receptor antagonist	158
Histamine-1 receptor antagonist	335
HMG-CoA reductase inhibitor	534
Interleukin-12 antagonist	149
Interleukin-17A antagonist	274
Interleukin-6 receptor antagonist	1,499
Janus kinase inhibitor	160
Kinase inhibitor	947
Leukotriene receptor antagonist	209
Loop diuretic	165
Nonsteroidal anti-inflammatory drug	954
Opioid agonist	651
Phosphodiesterase 4 inhibitor	175
Poly(ADP-Ribose) polymerase inhibitor	111
Proton pump inhibitor	440
Purine antimetabolite	108
Selective T cell costimulation modulator	491
Serotonin and norepinephrine reuptake inhibitor	125
Serotonin reuptake inhibitor	171
Somatostatin analog	1,492
Sphingosine 1-phosphate receptor modulator	104
Thiazide diuretic	142
Tumor necrosis factor blocker	2,577
Vascular endothelial growth factor inhibitor	169

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Blood pressure systolic increased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Blood pressure systolic increased
Age	Reports	Share
Under 2	28	0.1%
2 to 11	56	0.3%
12 to 17	79	0.4%
18 to 44	1,479	7.7%
45 to 64	5,001	26%
65 to 74	4,176	21.7%
75 and over	3,480	18.1%
Age not given	4,971	25.8%

Sex of the patient in the reports that record Blood pressure systolic increased
Sex	Reports	Share
Female	9,985	51.8%
Male	6,265	32.5%
Unknown or not given	3,020	15.7%

Age and sex are as the report gives them. 24.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Blood pressure systolic increased: adverse event reports that record this term. https://reportedreactions.com/reaction/blood-pressure-systolic-increased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Blood pressure systolic increased mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page